Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 6, 2012, Pages

  Sanchez Niño, Maria Dolores ^b   Bozic, Milica ^a   Córdoba Lanús, Elizabeth ^c   Valcheva, Petya ^a   Gracia, Olga ^a   Ibarz, Merce ^a   Fernandez, Elvira ^a   Navarro Gonzalez, Juan F ^c   Ortiz, Alberto ^b   Valdivielso, Jose Manuel ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Glomerular disease; Interleukins; Microalbuminuria

Indexed keywords

CALCITRIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARICALCITOL; VITAMIN D RECEPTOR;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXPERIMENTAL MODEL; GLOMERULUS FILTRATION; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MACROPHAGE; MALE; NEPHRITIS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 84858234310     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00090.2011     Document Type: Article

References (41)

1. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823-2828, 2005.
2. Bozic M, de Rooij J, Parisi E, Ortega MR, Fernandez E, Valdivielso JM. Glutamatergic signaling maintains the epithelial phenotype of proximal tubular cells. J Am Soc Nephrol 22: 1099-1111, 2011.
3. Branisteanu DD, Leenaerts P, Vandamme B, Bouillon R. Partial prevention of active Heymann nephritis by 1-alpha,25 dihydroxyvitamin D-3. Clin Exp Immunol 94: 412-417, 1993.
4. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant 21: 889-897, 2006.
5. Deb DK, Chen YZ, Zhang ZY, Zhang Y, Szeto FL, Wong KE, Kong J, Li YC. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-_B pathway. Am J Physiol Renal Physiol 296: F1212-F1218, 2009.
6. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, Kong J, Shi H, Chang A, Li YC. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 77: 1000-1009, 2010.
7. Deng A, Munger KA, Valdivielso JM, Satriano J, Lortie M, Blantz RC, Thomson SC. Increased expression of ornithine decarboxylase in distal tubules of early diabetic rat kidneys: are polyamines paracrine hypertrophic factors? Diabetes 52: 1235-1239, 2003.
8. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376: 1543-1551, 2010.
9. Durvasula RV, Shankland SJ. Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol 294: F830-F839, 2008.
10. Egido J, Gomez-Chiarri M, Ortiz A, Bustos C, Alonso J, Gomez-Guerrero C, Gomez-Garre D, Lopez-Armada MJ, Plaza J, Gonzalez E. Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases. Kidney Int Suppl 39: S59-S64, 1993.
11. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 54: 647-652, 2009.
12. Fukuda M, Carlsson SR. Leukosialin, a major sialoglycoprotein on human leukocytes as differentiation antigens. Med Biol 64: 335-343,1986.
13. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, Ritz E, Amann K. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 286: F526-F533, 2004.
14. Li YC, Kong J, Wei MJ, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D-3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002.
15. Matsui I, Hamano T, Tomida K, Inoue K, Takabatake Y, Nagasawa Y, Kawada N, Ito T, Kawachi H, Rakugi H, Imai E, Isaka Y. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 24: 2354-2361, 2009.
16. Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 53: 468-470, 2009.
17. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 18: 1796-1806, 2007.
18. Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52: 605-608, 2003.
19. Mundel P, Kriz W. Cell culture of podocytes. Exp Nephrol 4: 263-266,1996.
20. Navarro JF, Milena FJ, Mora C, Leon C, Claverie F, Flores C, Garcia J. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensinconverting enzyme inhibition. Kidney Int Suppl S98-S102, 2005.
21. Navarro JF, Milena FJ, Mora C, Leon C, Garcia J. Renal proinflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26: 562-570, 2006.
22. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433-442, 2008.
23. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, Palla R, Tetta C, Camussi G. Effects of 1,25(OH)2D-3 in experimental mesangial proliferative nephritis in rats. Kidney Int 60: 87-95, 2001.
24. Parisi E, Almaden Y, Ibarz M, Panizo S, Cardus A, Rodriguez M, Fernandez E, Valdivielso JM. N-methyl-D-aspartate receptors are expressed in rat parathyroid gland and regulate PTH secretion. Am J Physiol Renal Physiol 296: F1291-F1296, 2009.
25. Rodriguez-Lopez AM, Flores O, Arevalo MA, Lopez-Novoa JM. Tubular cell apoptosis and proliferation in the early phase of renal damage in uninephrectomized SHR. Kidney Blood Pressure Res 25: 13-19, 2002.
26. Sanchez-Nino MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 26: 1797-1802, 2010.
27. Sanchez-Nino MD, Sanz AB, Lorz C, Gnirke A, Rastaldi MP, Nair V, Egido J, Ruiz-Ortega M, Kretzler M, Ortiz A. BASP1 promotes apoptosis in diabetic nephropathy. J Am Soc Nephrol 21: 610-621, 2010.
28. Sanz AB, Justo P, Sanchez-Nino MD, Blanco-Colio LM, Winkles JA, Kreztler M, Jakubowski A, Blanco J, Egido J, Ruiz-Ortega M, Ortiz A. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 19: 695-703, 2008.
29. Sanz AB, Sanchez-Nino MD, Ramos AM, Moreno JA, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A. NF-kappa B in renal inflammation. J Am Soc Nephrol 21: 1254-1262, 2010.
30. Schena FP. Cytokine network and resident renal cells in glomerular diseases. Nephrol Dial Transplant 14, Suppl 1: 22-26, 1999.
31. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25(OH)2 vitamin D-3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53: 1696-1705, 1998.
32. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19: 1741-1752, 2008.
33. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court Aganna E, Price CP, Boucher BJ. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 95: 787-796, 2002.
34. Valdivielso JM. The physiology of vitamin D receptor activation. Contrib Nephrol 163: 206-212, 2009.
35. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634, 2005.
36. Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, Warram JH, Krolewski AS. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol 19: 789-797, 2008.
37. Wong CK, Ho AW, Tong PC, Yeung CY, Kong AP, Lun SW, Chan JC, Lam CW. Aberrant activation profile of cytokines and mitogenactivated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol 149: 123-131, 2007.
38. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282: 29821-29830, 2007.
39. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, Li YC. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 73: 163-171, 2008.
40. Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, Li X, Kong J, Li YC. 1,25-Dihydroxyvitamin D3 targeting of NF-[kappa]B suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 72: 193-201, 2007.
41. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105: 15896-15901, 2008.